spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound

Merck Millipore BioMonitoring

Leading science company to provide its product and services to Y-mAbs Therapeutics Inc

  • Includes scale-up and GMP manufacturing of drugs in late-stage development
  • Antibody targets advanced, refractory brain tumors in pediatric patients
Darmstadt, Germany, August 1, 2016 - Merck, a leading science and technology company, will provide its Provantage® End-to-End development and manufacturing services to Y-mAbs Therapeutics, Inc. in support of Y-mAbs' monoclonal antibody in late stage clinical development.

The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs' lead cell line to Merck, services will include scale-up and GMP manufacturing of an antibody currently in late stage clinical development.

"Pediatric brain cancer is an especially challenging therapeutic area that comes with an extreme sense of urgency," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "Through our Provantage® services, which offer a templated, nimble approach to development and manufacturing, we expect to accelerate progress of this innovative therapeutic for patients in need."

"Through our agreement with Merck, Y-mAbs takes a major step towards our commitment of making these breakthrough pediatric treatments available to children with advanced and life-threatening cancers,"said Thomas Gad, Y-mAbs' Founder, President and Head of Business Development and Strategy. "We expect to take delivery of cGMP drug product for our planned clinical trials by first half of 2017, and we are committed to making this leading immunotherapy product available to patients with life-threatening diseases worldwide."

Merck's Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate the progression of molecules into the clinic and toward commercialisation. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialisation.
phone +49(0)6151 720
web www.merckmillipore.com
email Frankfurter Str. 250 64293 Darmstadt Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Denny Bros Group continues its support of Packaging Innovations

A world leading print company is preparing to showcase its renowned labelling and printing solutions at next month’s prestigious Packaging Innovations show.
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

Adaptive Designs in Clinical Trials

9-10 April 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London, UK

Now running for 10 years, SMi’s annual conference on Adaptive Designs in Clinical Trials will return to London on 9thand 10th April 2018. This year’s agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement